Cardiogenic potential of endothelial progenitor cells
Satoshi Murasawa1, Takayuki Asahara
1Group of Vascular Regeneration, Institute of Biomedical Research and Innovation, Kobe, Japan. mura17@aol.com
Insights
Endothelial progenitor cell (EPC) transplantation shows promise for ischemic diseases, but cell scarcity is a challenge. Strategies to enhance EPC number or function are crucial for effective therapeutic outcomes.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Cell Therapy
Background:
- Endothelial progenitor cells (EPCs) are vital for repairing damaged blood vessels.
- EPC transplantation is a potential therapy for ischemic heart disease and peripheral artery disease (PAD).
- Limited EPC numbers in peripheral blood can hinder therapeutic efficacy.
Purpose of the Study:
- To review strategies for overcoming EPC scarcity in transplantation therapies.
- To explore the potential of EPCs in promoting cardiomyogenesis (heart muscle formation).
- To focus on EPC transplantation methods and their role in cardiac regeneration.
Main Methods:
- Review of existing literature on EPC expansion and modification techniques.
- Analysis of studies investigating EPC cardiomyogenic potential.
- Discussion of in vivo/ex vivo expansion, local injection, and gene transfer strategies for EPCs.
Main Results:
- Several strategies exist to increase EPC numbers or enhance their function for therapeutic use.
- EPCs demonstrate potential for contributing to heart muscle regeneration.
- Optimizing EPC delivery and function is key to improving outcomes in ischemic conditions.
Conclusions:
- Addressing EPC scarcity is critical for successful cell-based therapies in ischemic diseases.
- EPCs hold promise not only for vascular repair but also for cardiac regeneration.
- Further research into EPC expansion and cardiomyogenesis will advance regenerative medicine approaches.
Abstract:
Transplantation of endothelial progenitor cells (EPCs) are one of the promising strategies to recover the capillary flow in ischaemic diseases such as ischaemic heart disease and peripheral artery disease (PAD) in the leg. However, our previous and another group's works suggested the scarcity of the number of EPCs in peripheral blood might cause insufficient effect for the ischaemic diseases. There are several strategies to overcome this issue, such as (1) in vivo EPC expansion; (2) ex vivo EPC expansion; (3) local (not systemic) EPC injection; and (4) modification of EPC by gene transfer. Recent publications from our own and other groups have reported the possibility of cardiogenic potential of EPCs. We would like to focus on the strategies of EPC transplantation and cardiomyogenesis of EPCs in this review.
